Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 6Breast 3Thoracic 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Fallopian Tube Mucinous Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 101Specimen Handling 82pembrolizumab 78enzalutamide 63Nivolumab 60Gemcitabine 54Docetaxel 52apalutamide 42Radiosurgery 41Abiraterone Acetate 40Prednisone 39Androgen Antagonists 39Biopsy 37darolutamide 36Cisplatin 35cabozantinib 33Radiotherapy 32Carboplatin 29Pluvicto 28enfortumab vedotin 27abiraterone 27Ipilimumab 25Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 19X-Rays 19Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cediranib × Genitourinary × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT02893917 2026-05-28

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
90 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡